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lymphohistiocytosis in HIV-infected patients
We found the paper by De Santis et al. on the hematological
abnormalities in HIV-infected patients very interesting.1 However,
we think that the possible diagnosis of secondary hemophagocytic
lymphohistiocytosis (HLH) should also have been considered in
HIV-infected patients with cytopenias (affecting 2 or 3 lineages in
the peripheral blood).
HLH is a potentially fatal hyperinﬂammatory syndrome
characterized by histiocyte proliferation and hemophagocytosis.
HLH may be inherited (primary, familial), occurring generally in
infants, or may be secondary to any severe infection, malignancy,
or rheumatologic condition, occurring at any age. HLH is diagnosed
using clinical criteria developed by the HLH Study Group of the
Histiocyte Society (Table 1).2,3 The mechanism behind secondary
HLH is not well understood, and its clinical picture may be identical
to primary HLH, but there is more variability in severity and
outcome.4 HLH is considered to be due to a deﬁciency in cytolytic
activity resulting in persistent activation of lymphocytes and
histiocytes. This uncontrolled immune response leads to hyperse-
cretion of pro-inﬂammatory cytokines, an up-regulation ofTable 1
Hemophagocytic lymphohistiocytosis (HLH) 2004 diagnostic criteria (modiﬁed
from Henter et al.3)
The diagnosis of HLH can be established if one of either 1 or 2 below is
fulﬁlled:
1. A molecular diagnosis consistent with HLH
2. Diagnostic criteria for HLH are fulﬁlled (ﬁve out of the eight criteria below):
 Fever
 Splenomegaly
 Cytopenias (affecting 2 or 3 lineages in the peripheral blood):
Hemoglobin <90 g/l (in infants <4 weeks: hemoglobin <100 g/l)
Platelets <100  109/l
Neutrophils < 1  109/l
 Hypertriglyceridemia and/or hypoﬁbrinogenemia:
Fasting triglycerides 265 mg/dl
Fibrinogen 1.5 g/
 Hemophagocytosis in bone marrow or spleen or lymph nodes
 Low or absent NK-cell activity
 Ferritin 500 mg/l
 Soluble CD25 2400 U/l
Comments:
If hemophagocytic activity is not proven at the time of presentation, further search
for hemophagocytic activity is encouraged. If the bone marrow specimen is not
conclusive, material may be obtained from other organs. Serial marrow aspirates
over time may also be helpful.
The following ﬁndings may provide strong supportive evidence for the diagnosis:
(a) spinal ﬂuid pleocytosis (mononuclear cells) and/or elevated spinal ﬂuid protein,
(b) histological picture in the liver resembling chronic persistent hepatitis (biopsy).
Other abnormal clinical and laboratory ﬁndings consistent with the diagnosis are:
cerebromeningeal symptoms, lymph node enlargement, jaundice, edema, and skin
rash. Hepatic enzyme abnormalities, hypoproteinemia, hyponatremia, increased
VLDL, decreased HDL.
VLDL, very low density lipoprotein; HDL, high density lipoprotein.
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macrophages, and an expansion of inﬂammatory monocytes. This
exaggerated inﬂammatory response is responsible for necrosis and
organ failure, and results in uncontrolled proliferation and
phagocytic activity of histiocytes.5
HIV alone or in the presence of other opportunistic and non-
opportunistic infections or malignancies has been associated with
HLH, and HLH has also been described in the setting of immune
reconstitution inﬂammatory syndrome.5 In PubMed there are at
least 82 papers in which the association of ‘HIV’ with ‘hemopha-
gocytic’ or ‘haemophagocytic’ is present. Five studies report series
with more than ﬁve cases, with a mortality ranging from 31% to
100%.6–10 A recent retrospective study by Fardet et al. describes the
characteristics of 58 HIV-infected patients with secondary HLH. At
the time of HLH, the median duration of HIV infection was 4 years
and 57% were receiving highly-active antiretroviral therapy. The
median CD4 lymphocyte count was 91/ml and 35% of patients had a
plasma HIV-1 RNA less than 50 copies/ml. An underlying hemo-
pathy/malignancy (Hodgkin lymphoma n = 10) or infection (tuber-
culosis n = 9, cytomegalovirus n = 5) was present in 31 patients.9
Clinicians need to be aware of the occurrence of HLH in HIV-
infected patients. Further studies are needed to understand
whether an immunosuppressive treatment such as treatment
with steroids or with an etoposide-containing regimen could be
beneﬁcial in those cases that do not respond promptly to anti-
infective therapy.
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